Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

From BugSigDB
Reviewed Marked as Reviewed by Svetlana up on 2025-2-14
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M
Journal
Gastroenterology
Year
2012
Alterations in intestinal microbiota are associated with obesity and insulin resistance. We studied the effects of infusing intestinal microbiota from lean donors to male recipients with metabolic syndrome on the recipients' microbiota composition and glucose metabolism. Subjects were assigned randomly to groups that were given small intestinal infusions of allogenic or autologous microbiota. Six weeks after infusion of microbiota from lean donors, insulin sensitivity of recipients increased (median rate of glucose disappearance changed from 26.2 to 45.3 μmol/kg/min; P < .05) along with levels of butyrate-producing intestinal microbiota. Intestinal microbiota might be developed as therapeutic agents to increase insulin sensitivity in humans; www.trialregister.nl; registered at the Dutch Trial Register (NTR1776).

Experiment 1


Reviewed Marked as Reviewed by Svetlana up on 2025-2-14

Curated date: 2025/02/04

Curator: Aleru Divine

Revision editor(s): Aleru Divine, WikiWorks

Subjects

Location of subjects
Netherlands
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Response to transplant Response to transplant,response to transplant
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Allogenic (Baseline samples)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Allogenic (6 weeks samples)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Fecal samples collected from the participants 6 weeks after allogenic lean donor gut microbiota treatment.
Group 0 sample size Number of subjects in the control (unexposed) group
9
Group 1 sample size Number of subjects in the case (exposed) group
9
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
3 months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Human Intestinal Tract Chip

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mixed-Effects Regression
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes


Signature 1

Reviewed Marked as Reviewed by Svetlana up on 2025-2-14

Curated date: 2025/02/04

Curator: Aleru Divine

Revision editor(s): Aleru Divine, WikiWorks

Source: Supplementary Table 3

Description: Significant changes in 16 fecal gut microbiota within the allogenic lean donor gut microbiota treatment group after 6 weeks

Abundance in Group 1: increased abundance in Allogenic (6 weeks samples)

NCBI Quality ControlLinks
Dorea formicigenerans
Mediterraneibacter gnavus
Lacrimispora sphenoides
[Clostridium] symbiosum
Coprobacillus cateniformis
Thomasclavelia ramosa
Aneurinibacillus
[Ruminococcus] lactaris
[Clostridium] nexile
Anaerotruncus colihominis
[Eubacterium] siraeum
Sporobacter termitidis
Oxalobacter formigenes
Ruminococcus callidus
Ruminococcus bromii
Ruminococcus intestinalis

Revision editor(s): Aleru Divine, WikiWorks

Experiment 3


Reviewed Marked as Reviewed by Svetlana up on 2025-2-14

Curated date: 2025/02/04

Curator:

Revision editor(s):

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Autologous (6 weeks samples)

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by Svetlana up on 2025-2-14

Curated date: 2025/02/04

Curator: Aleru Divine

Revision editor(s): Aleru Divine, WikiWorks

Source: Supplementary Table 3

Description: Differences in gut microbiota identified between allogenic and autologous treatment groups.

Abundance in Group 1: increased abundance in

NCBI Quality ControlLinks
Dorea formicigenerans
Lacrimispora sphenoides
Coprobacillus cateniformis
[Ruminococcus] lactaris
[Clostridium] nexile
Oxalobacter formigenes

Revision editor(s): Aleru Divine, WikiWorks

Experiment 4


Reviewed Marked as Reviewed by Svetlana up on 2025-2-14

Curated date: 2025/02/04

Curator: Aleru Divine

Revision editor(s): Aleru Divine, WikiWorks

Differences from previous experiment shown

Subjects

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Small intestine Anterior intestine,Intestinum tenue,Mid intestine,Small bowel,Small intestine,small intestine
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Small intestinal biopsy samples collected from the participants 6 weeks after allogenic lean donor gut microbiota treatment.

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2025/02/04

Curator: Aleru Divine

Revision editor(s): Aleru Divine, WikiWorks

Source: Supplementary Table 4

Description: Differences in gut microbiota identified between allogenic and autologous treatment groups.

Abundance in Group 1: increased abundance in Allogenic (6 weeks samples)

NCBI Quality ControlLinks
Escherichia coli
Corynebacterium sp.
Alcaligenes faecalis

Revision editor(s): Aleru Divine, WikiWorks